drugset / Trial / NCT05243641
Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test
Phase 1/2
Terminated
10 enrolled
M.D. Anderson Cancer Center
Celcuity Inc · collabNovartis · collabPuma Biotechnology, Inc. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is to learn if the combination therapy of capmatinib and neritinib can help to control metastatic or locally advanced breast cancer. Researchers also want to find the highest tolerable dose of the combination therapy of capmatinib and neritinib that can be used in this study drug combinations. The safety of this drug combination and the CELsignia MP test methodology will also be studied.
Timeline
- Start
- 2022-08-18
- Primary completion
- 2024-11-19
- Completion
- 2024-11-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capmatinib | Small molecule | 400 mg | — |
| Subject | Neratinib | Small molecule | 160 mg | — |